抗性高血压的高血压和基于设备的治疗方法:最新的审查
Oluwaremilekun Tolu-Akinnawo1, David N Ray2, Tiwalade Awosanya3
1Internal Medicine, Meharry Medical College, Nashville, USA.
Cureus
|August 7, 2024
概括
新的基于设备的治疗方法正在出现,以管理不受控制的高血压,为药物提供替代品. 这些创新方法针对自主神经系统和其他途径有效降低血压.
科学领域:
- 心血管医学 心血管医学
- 医疗器械 医疗器械
- 干预心脏病学 干预心脏病学
背景情况:
- 高血压是心血管死亡的主要可修改风险因素,影响全球13亿人.
- 尽管有可用的药物,但很大一部分高血压患者仍然无法控制.
- 需要新的治疗策略来管理耐性高血压及其并发症.
研究的目的:
- 审查目前和新兴的基于器件的干预措施,用于动脉高血压管理.
- 讨论最近批准的和正在研究的调节自主神经系统和其他生理路径的设备.
主要方法:
- 对最近获得FDA批准的器械进行审查,包括脏剥皮 (RDN).
- 讨论临床试验中的基于试验设备的治疗方法.
- 根据作用机制对设备进行分类 (例如神经调节,化学受体调节).
主要成果:
- 在2023年11月,两种损器 (RDN) 设备获得了FDA的批准.
- 研究性设备在临床测试中显示出降低血压的有希望的结果.
- 不同的设备类别针对不同的生理机制,包括自主神经系统活动.
结论:
- 基于设备的疗法代表了干预性高血压管理的不断增长的领域.
- 新兴技术为患有失控血压的患者提供了新的希望.
- 考虑到病理生理学和程序风险的个性化方法对于设备选择至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Antihypertensive Drugs: Direct Renin Inhibitors
517
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
517
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
151
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151
Antihypertensive Drugs: Angiotensin II Receptor Blockers
666
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
666


